HemoSonics Celebrates NIH Grant for Maternal Health Improvement
HemoSonics, a pioneering medical device company, has been awarded a significant grant from the National Institutes of Health (NIH) as part of their RADx Tech for Maternal Health Challenge. This initiative is geared towards enhancing postpartum maternal health and ensuring greater health equity through advanced diagnostics.
Addressing the Maternal Mortality Crisis
As maternal mortality rates remain a pressing challenge, HemoSonics has stepped up to address the critical issue of postpartum hemorrhage (PPH), recognized as the leading cause of maternal deaths globally. The company’s innovative Quantra Hemostasis System aims to revolutionize the management of peripartum bleeding among obstetric patients, thereby potentially saving lives.
Recognition from NIH
The NIH grant, amounting to $525,000, acknowledges HemoSonics' dedication to improving maternal health through innovative diagnostic solutions. HemoSonics was chosen from over 80 submissions, showcasing their commitment to reducing complications related to childbirth.
The Quantra Hemostasis System
HemoSonics' flagship product, the Quantra System, is already FDA-cleared for use in various surgical settings, including cardiovascular surgery and major orthopedic procedures. The technology offers reliable, rapid analysis of blood coagulation, crucial in emergency situations where rapid decision-making can be life-saving.
Utilizing Innovative Technology for Patient Care
This cutting-edge system employs SEER Sonorheometry, a proprietary ultrasound-based method that assesses the coagulation properties of blood samples. By minimizing resources while delivering fast results, the Quantra System enhances point-of-care testing, facilitating timely and effective patient management.
Commitment to Maternal Health
“Receiving the RADx award is a significant validation of our work at HemoSonics,” shared Bob Roda, President and CEO. “This funding will enable us to enhance technology aimed at ensuring that women everywhere can experience safe and healthy deliveries.” HemoSonics aims to contribute to a future where maternal health issues are effectively addressed.
Focus on Health Disparities
The IMPROVE initiative by NIH, which co-sponsored the RADx challenge, strives to target preventable maternal death causes. With an emphasis on underserved populations, the initiative brings attention to the need for equitable healthcare solutions in maternal health.
The Bigger Picture: Improving Health Outcomes
Overall, HemoSonics is committed to transforming patient outcomes in the realm of obstetrics and beyond. By focusing on innovative technologies, the organization plays a crucial role in the advancing field of acute bleeding management, all while striving to lower overall healthcare costs.
About HemoSonics
Founded with a mission to improve patient care, HemoSonics is at the forefront of technology development in acute bleeding management. Operating from Durham, North Carolina, the company aims to provide actionable information for healthcare providers, bridging gaps between diagnostic capabilities and patient outcomes.
Frequently Asked Questions
What is the significance of the NIH grant awarded to HemoSonics?
The NIH grant supports HemoSonics’ innovative research aimed at reducing maternal mortality through advanced diagnostic solutions.
What technology does the Quantra System utilize?
The Quantra System uses SEER Sonorheometry, a proprietary method that utilizes ultrasound technology to assess blood coagulation rapidly and accurately.
Why is postpartum hemorrhage a concern in maternal health?
Postpartum hemorrhage is the leading cause of maternal mortality worldwide, affecting millions of women and necessitating effective management solutions.
How does HemoSonics plan to advance maternal health?
HemoSonics aims to enhance maternal health through technology that improves bleeding management in obstetric patients and promotes healthier pregnancy outcomes.
Where can I learn more about HemoSonics?
For more information about HemoSonics and its innovative solutions, visit the company's official website.
